Clinical Trials

Date: 2017-01-05

Type of information: Initiation of development program

phase: 1

Announcement: initiation of development program

Company: Adocia (France)

Product: BioChaperone Lispro® (insuline lispro) and Symlin® (pramlintide), BioChaperone Lispro® (insuline lispro) and Byetta®(exenatide)

Action mechanism:

• insulin analogue/amylin analogue/GLP-1 receptor agonist. BioChaperone Lispro® is an ultra-fast acting formulation of insulin Lispro - Humalog® licensed to Lilly. This formulation uses Adocia’s proprietary technology BioChaperone, which is designed to accelerate insulin absorption.
• Pramlintide (Symlin®, AstraZeneca) is an amylin analogue  and  exenatide (Byetta®, AstraZeneca) is a GLP-1 receptor agonist.

Disease: type 1 diabetes

Therapeutic area: Metabolic diseases

Country:

Trial details:

Latest news: • On January 5, 2017, Adocia announced the launch of two new projects employing its proprietary BioChaperone® technology: the combination of insulin lispro with pramlintide (amylin analogue, Symlin®, AstraZeneca) and the combination of insulin lispro with exenatide (GLP-1 receptor agonist, Byetta®, AstraZeneca). Adocia aims to test one of these candidates in a clinical study in Q4 2017.

Is general: Yes